Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont
versus placebo administered for 24 weeks in approximately 165 adult subjects with classic CAH
due to 21-hydroxylase deficiency. The study consists of a 6 month randomized, double blind,
placebo-controlled period, followed by 1 year of treatment with crinecerfont. Duration of
participation is approximately 20 months.